Novel and Emerging Therapeutic Strategies in the Management of
Hematologic Disorder-Related Anemia — Part 1: Our interview with Dr
Komrokji highlights the following topics and cases from his
practice.
Approved and emerging therapies for patients with
transfusion-dependent myelodysplastic syndromes (MDS); mechanism of
action of the investigational erythroid maturation agent (EMA)
luspatercept (00:00)
Design, entry criteria and outcomes of the Phase III MEDALIST
trial of luspatercept for the treatment of anemia in patients with
very low-, low- or intermediate-risk MDS with ring sideroblasts who
require red blood cell (RBC) transfusions (2:10)
Clinical experience with the EMAs luspatercept and sotatercept
(6:03)
Potential FDA approval of luspatercept for the management of
low-risk MDS (9:11)
Ongoing investigation of luspatercept-based strategies for MDS
(12:25)
Investigation of venetoclax in combination with a
hypomethylating agent for higher-risk MDS (16:00)
Role of luspatercept in myelofibrosis; predictors of benefit
from luspatercept (18:24)
Case: A man in his mid-70s presents with
fatigue and dyspnea and is diagnosed with lower-risk MDS with ring
sideroblasts (21:17)
Initial workup and diagnosis for patients with MDS (23:58)
Risk stratification in MDS and therapeutic options for patients
at lower versus higher risk (25:52)
Clinical experience with EMAs for lower-risk, RBC
transfusion-dependent MDS (29:42)
Monitoring and management of iron overload in patients with
lower-risk, RBC transfusion-dependent MDS (32:30)
Case: A man in his early 60s with
lenalidomide-refractory, lower-risk MDS and a del(5q) mutation
receives the telomerase inhibitor imetelstat on a clinical trial
(36:09)
Case: A man in his mid-70s with
postpolycythemia vera myelofibrosis with anemia and splenomegaly
receives initial ruxolitinib therapy (40:49)
Activity and tolerability of JAK1/2 inhibitors in myelofibrosis
(45:09)
Case: A woman in her mid-70s with
myelofibrosis and a JAK2 mutation presents with progressive
splenomegaly and anemia and receives ruxolitinib (48:31)
Novel agents and strategies under investigation for
myeloproliferative neoplasms (MPNs) (50:40)
Incidence of IDH1/2 mutations in patients with MPNs; responses
to IDH1/2 inhibitors and ongoing clinical investigations
(53:13)
Activity of the antifibrotic immunomodulator PRM-151 in
patients with myelofibrosis (56:04)
Common misconceptions about the use of
erythropoietin-stimulating agents (57:45)
Perspective on the appropriate choice of therapy for patients
with intermediate-2 or high-risk myelofibrosis (1:01:41)
Lack of correlation between JAK2 mutation status and response
to ruxolitinib (1:03:19)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.